𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Neurophysiologic evaluation and clinical trials for neuromuscular diseases

✍ Scribed by Richard K. Olney

Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
70 KB
Volume
21
Category
Article
ISSN
0148-639X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Therapeutic trials in neuromuscular dise
Therapeutic trials in neuromuscular diseases
✍ Walter G. Bradley πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 76 KB

T h e treatment of a disease may spring from an understanding of the underlying etiology of that disease, or it may arise less directly. For instance, the use of L-dopa in the treatment of Parkinson's disease arose from the finding of deficient dopamine levels in the brains o f Parkinsonian patients

Endpoints for clinical trials evaluating
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease
✍ Geert R. D'Haens; Richard Fedorak; Marc LΓ©mann; Brian G. Feagan; Michael A. Kamm πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 91 KB πŸ‘ 1 views

The management of Crohn's disease is rapidly changing. The advent of potent immunomodulatory and biologic therapies has led to more demanding endpoints for clinical trials than only clinical response and remission. Complete withdrawal of corticosteroids, healing of endoscopically visible lesions, an

Neuromuscular disease: Evidence and anal
Neuromuscular disease: Evidence and analysis in clinical neurology
✍ S. Claiborne Johnston πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 38 KB

A lack of high-quality evidence often forces us to rely on other sources of information, such as clinical experience, expert opinion, and extrapolation from pathophysiology, to make decisions about patient management. After years of practice, we began to accept these "truths" from nonempirical evide